Welcome to our dedicated page for Alibaba Group Holding SEC filings (Ticker: BABAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Alibaba Group Holding's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Alibaba Group Holding's regulatory disclosures and financial reporting.
Alibaba Group Holding Ltd (BABA) director Joseph C. Tsai reported an indirect open‑market purchase of 720,000 Ordinary Shares on 2026-08-25 at $14.47 per share, with the U.S. dollar price derived using an exchange rate of HK$7.8412 to US$1.00. After this trade, an affiliated corporation held 114,979,168 shares indirectly, while Tsai also held 825,238 shares directly and 1,280,000 shares were held indirectly by his spouse. The filing notes that additional shares held by Joe and Clara Tsai Foundation Limited and Parufam Limited are excluded, and Tsai disclaims any pecuniary interest or beneficial ownership in those for Section 16 purposes.
Alibaba Group Holding Ltd (BABA) director Joseph C. Tsai, through a corporation, purchased 720,000 Ordinary Shares on 2026-08-24 at $14.29 per share, a price translated from Hong Kong dollars at HK$7.8412 to US$1.00. The shares are reported as indirectly owned by a corporation.
After this transaction, he is reported as having 114,259,168 Ordinary Shares held indirectly through a corporation, 825,238 shares held directly, and 1,280,000 shares held indirectly by his spouse. The report notes that separate holdings of Joe and Clara Tsai Foundation Limited and Parufam Limited are excluded and that he disclaims pecuniary interest in those shares.
Alibaba Group Holding Ltd (BABA) reports that its board granted new equity Awards under the 2024 Equity Incentive Plan on August 22, 2026. The grant covers 1,932,300 underlying Shares, equal to approximately 0.01% of total Shares in issue (excluding treasury shares), to certain Employees, with no grantee being a director, chief executive, substantial shareholder, or their associate. The Awards have a purchase price of nil and were granted when the Shares closed at HK$123.00 per Share. Vesting follows mixed schedules in tranches over up to 4 years, with some Awards vesting within 12 months, and they carry no performance targets but are subject to a detailed clawback mechanism. After this grant, up to 338,510,773 Shares remain available for future grants under the 2024 Plan and up to 93,716,369 Shares remain available under the service provider sub-limit.
Alibaba Group Holding Ltd (BABA) has priced a primary equity placing in Hong Kong of 710,000,000 new ordinary shares at HK$112.70 per share, for total gross proceeds of HK$80.0 billion. The shares are being placed to non-U.S. persons outside the United States under Regulation S and are issued under the company’s Hong Kong general mandate.
The deal is expected to close on August 26, 2026, subject to customary conditions and Hong Kong Stock Exchange listing approval. Net proceeds are expected to be about HK$79.7 billion, which Alibaba intends to use 100% to invest in its full-stack AI capabilities, including expanding and enhancing AI infrastructure.
The 710,000,000 new shares represent approximately 3.70% of the existing 19,174,988,918 shares in issue and about 3.57% of the enlarged 19,884,988,918 shares after completion. Alibaba has agreed to a 90-day lock-up on additional equity issuances, with customary carve-outs for existing share incentive plans.
Alibaba Group Holding Ltd (BABA) reported that Chief Executive Officer and director Wu Yongming purchased 350,000 Ordinary Shares on 2026-08-24 in an open-market or private transaction. The weighted average purchase price was $14.24 per share, based on multiple trades executed in Hong Kong dollars between HK$110.70 and HK$112.40 and converted at HK$7.8412 to US$1.00.
Following this transaction, Wu directly held 1,364,418 Ordinary Shares. In addition, the filing reports 108,000 Ordinary Shares held indirectly by his spouse and 12,320,000 Ordinary Shares held indirectly by a trust.
Alibaba Group Holding Ltd (BABA) reported June quarter 2026 revenue of RMB268,953 million (US$39,639 million), up 9% year-over-year, while profitability declined sharply as it accelerated AI investments and absorbed regulatory and impairment charges.
Net income fell to RMB10,444 million, down 75%, and operating margin contracted from 14% to 6%, driven by higher cost of revenue, increased product development and general and administrative expenses, including a provision related to a EUR550 million European Commission Digital Services Act fine, plus RMB4,458 million goodwill impairment. Non-GAAP net income declined 38% to RMB20,715 million.
Segment trends diverged. The new AI Cloud and Compute Services segment grew revenue 45% to RMB48,437 million with adjusted EBITA up 133% to RMB5,628 million, supported by AI product revenue of RMB12,376 million. China Quick Commerce grew 45%, while China E-commerce revenue fell 8%. AI Labs and Applications revenue rose 16% but its adjusted EBITA loss widened to RMB13,861 million as Alibaba invested heavily in Qwen models and applications. Free cash flow was an outflow of RMB44,670 million amid a 75% increase in capital expenditures to RMB67,678 million, largely for AI infrastructure; Alibaba also repurchased US$162 million of shares.
Alibaba Group Holding Ltd filed a quarterly Form 13F as an institutional investment manager, signed by Company Secretary Jinwei Zhang. The report is a full 13F holdings report, not a notice or combination filing. It lists 2 reportable positions in the Form 13F Information Table with an aggregate reported value of $509,372,952, rounded to the nearest dollar, and indicates there are no other included managers.
Alibaba Group Holding Limited reports an anti-dilution adjustment to the terms of its HK$12.023 billion zero coupon exchangeable bonds due 2032, which are exchangeable into shares of Alibaba Health Information Technology Limited. The change is triggered by Alibaba Health’s approved final dividend of RMB0.0595 per share and special dividend of RMB0.1352 per share for the year ended March 31, 2026.
The Exchange Price of the 2025 Bonds is reduced from HK$6.23 to HK$5.92 per Alibaba Health share and the Exchange Ratio is increased from 160,513.6 to 168,918.9 Alibaba Health shares per HK$1,000,000 principal amount of bonds, effective August 14, 2026. As a result, the maximum number of Alibaba Health shares deliverable upon full exchange of the bonds increases from 1,928,855,537 to 2,030,912,162 shares.
Alibaba Group Holding Limited has scheduled a board meeting on August 19, 2026 to discuss its unaudited results for the three months ended June 30, 2026.
The results and a related announcement will be approved by or on behalf of the board and released on August 20, 2026. The announcement also lists the current board composition, including chairman Joseph C. Tsai, several other directors and multiple independent directors.